+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression



A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression



Journal of Clinical Psychopharmacology 15(4 Suppl 2): 41s-45s



In a multicenter study of 78 severely depressed inpatients (44 women and 34 men; age range, 23 to 70 years), the efficacy, onset of efficacy, and tolerability of the reversible monoamine oxidaseA inhibitor moclobemide (450 mg/day) in combination with thioridazine (100 mg/day) were compared with those of moclobemide (450 mg/day) plus placebo. Patients enrolled met the DSM-III-R criteria for severe depression and had a severity score of at least 20 on the first 17 items of the Hamilton Rating Scale for Depression (HAM-D). Additionally, these patients had not responded to at least two standard antidepressants during the 2 years preceding screening and the mean duration of the current episode was 6 months. After a washout period of 3 to 5 days, patients were randomized to one of the two treatment groups, which at the outset had similar characteristics. Efficacy was assessed by the HAM-D, a depression observation rating for nurses, and a Clinical Global Impression (CGI) scale. Tolerability assessments included an overall rating, a description of adverse events, vital signs, electrocardiogram, and laboratory tests. After 4 weeks of therapy, both groups of patients showed significant improvements in HAM-D and CGI scores. The response rates (based on HAM-D gtoreq 50% decrease) were 74% for moclobemide/thioridazine and 77% for moclobemide/placebo, and according to CGI scores, 76 and 72% were "very much improved" or "much improved," respectively. Onset of effect was noted after 9.2 and 9.8 days, respectively. Overall tolerability at the end of the study was rated "very good" or "good" in 89% of the moclobemide/thioridazine group and in 88% of the moclobemide/placebo group. This study demonstrates that moclobemide is effective and well tolerated in the treatment of resistant, severely depressed patients. The addition of thioridazine to moclobemide did not increase efficacy or speed of onset, nor did it significantly impair tolerability.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 008020529

Download citation: RISBibTeXText

PMID: 7593730


Related references

A double-blind placebo-controlled comparison of moclobemide and amitriptyline in the treatment of depression. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 37 Suppl 1: 12-17, 1992

Moclobemide versus clomipramine in the treatment of depression: a double-blind multicentre study in Belgium. Acta Psychiatrica Scandinavica. Supplementum 360: 50-51, 1990

Moclobemide versus amitriptyline in the treatment of depression: two small double-blind multicentre studies in Belgium. Acta Psychiatrica Scandinavica. Supplementum 360: 52-53, 1990

Lack of efficacy of moclobemide or imipramine in the treatment of recurrent brief depression: results from an exploratory randomized, double-blind, placebo-controlled treatment study. International Clinical Psychopharmacology 29(6): 339-343, 2015

Moclobemide and placebo in mild major depression: a double-blind randomized trial. Psychopharmacology 106 Suppl: S114-S115, 1992

Double-blind comparison of moclobemide, imipramine and placebo in depressive patients. Acta Psychiatrica Scandinavica. Supplementum 360: 54-56, 1990

Double-blind comparison of moclobemide and tranylcypromine in depression. Pharmacopsychiatry 26(6): 240-245, 1993

Moclobemide versus fluoxetine for double depression: A randomized double-blind study. Journal of Psychiatric Research 30(6): 453-458, 1996

Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. British Journal of Psychiatry 168(2): 149-157, 1996

Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial. British Journal of Psychiatry 160: 519-524, 1992

Comparative efficacy of antidepressants on anxiety features in depression: A meta-analysis of double-blind studies of imipramine and moclobemide against placebo. International Journal of Psychiatry in Clinical Practice 4(2): 111-117, 2000

The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience 247(2): 71-80, 1997

A controlled double-blind trial of moclobemide and imipramine in the treatment of depression. Singapore Medical Journal 36(1): 38-40, 1995

Moclobemide versus placebo in the treatment of depression: a multicentre study in Belgium. Acta Psychiatrica Scandinavica. Supplementum 360: 42, 1990

Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression. Acta Psychiatrica Belgica 92(6): 355-369, 1992